Hydrogel-Mediated Sustained Systemic Delivery of Mesenchymal Stem Cell-Derived Extracellular Vesicles Improves Hepatic Regeneration in Chronic Liver Failure

2019 ◽  
Vol 11 (41) ◽  
pp. 37421-37433 ◽  
Author(s):  
Soura Mardpour ◽  
Mohammad Hossein Ghanian ◽  
Hamid Sadeghi-abandansari ◽  
Saeid Mardpour ◽  
Abdoreza Nazari ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Liver Failure ◽  
Extracellular Vesicles ◽  
Chronic Liver ◽  
Hepatic Regeneration ◽  
Systemic Delivery ◽  
Chronic Liver Failure

scholarly journals Mesenchymal Stem Cell Transplantation for Liver Cell Failure: A New Direction and Option

2018 ◽  
Vol 2018 ◽  
pp. 1-10
Author(s):  
Yantian Cao ◽  
Bangjie Zhang ◽  
Rong Lin ◽  
Qingzhi Wang ◽  
Jie Wang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mesenchymal Stem Cell ◽  
Stem Cell Transplantation ◽  
Liver Failure ◽  
Cell Transplantation ◽  
Chronic Liver ◽  
Early Assessment ◽  
Chronic Liver Failure ◽  
Mesenchymal Stem Cell Transplantation ◽  
Beneficial Effects

Background and Aims. Mesenchymal stem cell transplantation (MSCT) became available with liver failure (LF), while the advantages of MSCs remain controversial. We aimed to assess clinical advantages of MSCT in patients with LF. Methods. Clinical researches reporting MSCT in LF patients were searched and included. Results. Nine articles (n=476) related with LF patients were enrolled. After MSCT, alanine aminotransferase (ALT) baseline decreased largely at half a month (P<0.05); total bilirubin (TBIL) baseline declined to a certain stable level of 78.57 μmol/L at 2 and 3 months (P<0.05). Notably, the decreased value (D value) of Model for End-Stage Liver Disease score (MELD) of acute-on-chronic liver failure (ACLF) group was higher than that of chronic liver failure (CLF) group (14.93 ± 1.24 versus 4.6 ± 5.66, P<0.05). Moreover, MELD baseline of ≥20 group was a higher D value of MELD than MELD baseline of <20 group with a significant statistical difference after MSCT (P=0.003). Conclusion. The early assessment of the efficacy of MSCT could be based on variations of ALT at half a month and TBIL at 2 and 3 months. And it had beneficial effects for patients with LF, especially in ACLF based on the D value of MELD.

scholarly journals Combination Treatments of Plasma Exchange and Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Clinical Trial in China

2019 ◽  
Vol 2019 ◽  
pp. 1-10 ◽  
Author(s):  
Wen-xiong Xu ◽  
Hong-liang He ◽  
Shun-wen Pan ◽  
Yuan-li Chen ◽  
Mei-ling Zhang ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Mesenchymal Stem Cell ◽  
Liver Failure ◽  
Plasma Exchange ◽  
Umbilical Cord ◽  
Unfavorable Outcome ◽  
Chronic Liver Failure ◽  
B Virus

Background. Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is a common type of liver failure with a high mortality. This study aimed at investigating the safety and efficacy of the combination treatment of plasma exchange (PE) and umbilical cord-derived mesenchymal stem cell (UC-MSCs) transplantation for HBV-ACLF patients.Methods. A total of 110 HBV-ACLF patients treated in our hospital from January 2012 to September 2017 were enrolled into this trial and divided into the control group (n=30), UC-MSC group (n=30), PE group (n=30), and UC-MSC + PE group (n=20) based on their treatments. The hepatic function, coagulation, and virological and immunological markers were assessed at baseline and 30, 60, 90, 180, and 360 days. The endpoint outcomes were death and unfavorable outcome (need for liver transplantation or death).Results. The UC-MSC + PE group had the lowest rates of death and unfavorable outcome at 30 days, 60 days, and 90 days posttreatment among the four groups, but the difference did not reach significances. The multivariate logistic regression analysis demonstrated that hemoglobin, prothrombin activity, and MELD (model for end-stage liver disease) score were the independent factors associated with the unfavorable outcome (allP<0.05). The levels of total bilirubin, alanine aminotransferase, aspartate transaminase, and MELD score were significantly decreased during treatments (allP<0.05).Conclusion. UC-MSCs combined with PE treatment had good safety but cannot significantly improve the short-term prognosis of HBV-ACLF patients with as compared with the single treatment. The long-term efficacy should be further evaluated. This trial is registered with registration no.NCT01724398.

Sign in / Sign up

Export Citation Format

Share Document